These data suggest that this personalized DC vaccine approach can bolster anti-tumor immune responses through two potential mechanisms: the induction of antigen-specific CD8+ T cells targeting neoantigens pulsed in the DC vaccine and the generation of new antigen-specific CD8+ T cells with TCR specificity against previously untargeted cancer epitopes. The gene discussed is CD8A; the disease is cancer.